HIV-associated facial lipoatrophy

Dermatol Surg. 2002 Nov;28(11):979-86. doi: 10.1046/j.1524-4725.2002.02099.x.

Abstract

Background: HIV-infected individuals are living long, healthy lives. They are now concerned with less life-threatening problems, especially lipodystrophy.

Objective: To review the current state of our knowledge about lipodystrophy in HIV-infected individuals.

Methods: The literature was reviewed and analyzed for relevant information. In addition, our clinical experience of managing such individuals was utilized.

Results: Lipodystrophy and facial lipoatrophy and their relationship to HIV-infection are discussed. Their differences are noted. The spectrum of appearance in individuals with facial lipoatrophy is described and a severity scale suggested which should be of value in assessing the results of treatment.

Conclusion: Lipodystrophy and lipoatrophy are intimately related to infection with HIV. In consequence, facial lipoatrophy is a major stigma for HIV-infected individuals and can have dramatic effects on their self-esteem and socialization. Effective treatment is essential.

Publication types

  • Review

MeSH terms

  • Antiretroviral Therapy, Highly Active / adverse effects
  • Face
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Protease Inhibitors / adverse effects*
  • HIV-1*
  • HIV-Associated Lipodystrophy Syndrome / etiology
  • HIV-Associated Lipodystrophy Syndrome / therapy*
  • Humans
  • Lipectomy
  • Risk Factors

Substances

  • HIV Protease Inhibitors